FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316481657> ?p ?o ?g. }

• W2316481657 endingPage "1363" @default.
• W2316481657 startingPage "1357" @default.
• W2316481657 abstract "The purpose of this study was to explore the uptake of the synthetic amino acid analog PET radiotracer anti-3-(18)F-FACBC ((18)F-fluciclovine) in breast lesions with correlation to histologic and immunohistochemical characteristics.Twelve women with breast lesions underwent 45-min dynamic PET/CT of the thorax after intravenous administration of 366.3 ± 14.8 (337.44-394.05) MBq of (18)F-fluciclovine. Uptake in the primary lesions at 4 representative time points (5, 17, 29, and 41 min) after injection were correlated with histologic, imaging, and clinical findings. The significance of differences in SUVmax and tumor-to-background ratios between malignant and benign tissue were calculated. Correlations of activity to histologic and immunohistochemical cancer subtypes were made including Ki-67 intensity and Nottingham grade (NG).There were 17 breast lesions (4 benign, 13 malignant) including 7 of 13 invasive ductal, 5 of 13 invasive lobular, and 1 of 13 metaplastic carcinomas. There was a significant difference in mean SUVmax ± SD of malignant (6.2 ± 3.2, 6.0 ± 3.2, 5.7 ± 2.8, and 5.6 ± 3.0) versus benign (1.3 ± 0.6, 1.2 ± 0.5, 1.2 ± 0.6, and 1.1 ± 0.5) lesions at 5, 17, 29, and 41 min, respectively (all P ≤ 0.0001). Tumor-to-background (aorta, normal breast, and marrow) ratios were also significantly higher in malignant than benign breast lesions (all P ≤ 0.02). The highest (18)F-fluciclovine activity seems to be present in triple-negative and NG3 subtypes. Across time points, quantitative Ki-67 had weak positive correlation with SUVmax (R1 = 0.48 [P = 0.03], R2 = 0.44 [P = 0.03], R3 = 0.46 [P = 0.03], R4 = 0.43 [0.06]). In 7 patients, (18)F-fluciclovine PET visualized locoregional and distant spread including that of lobular cancer, though identification of hepatic metastases was limited by physiologic background activity.The uptake characteristics of (18)F-fluciclovine are reflective of the histologic and immunohistochemical characteristics in suspected breast lesions with greater activity in malignant versus benign etiology. The data from this exploratory study may be useful to design future studies using (18)F-fluciclovine PET for breast tumor imaging as well as for detection of locoregional and distant spread." @default.
• W2316481657 created "2016-06-24" @default.
• W2316481657 creator A5000322709 @default.
• W2316481657 creator A5014634237 @default.
• W2316481657 creator A5017822819 @default.
• W2316481657 creator A5019871221 @default.
• W2316481657 creator A5025282563 @default.
• W2316481657 creator A5028983768 @default.
• W2316481657 creator A5029771057 @default.
• W2316481657 creator A5036023937 @default.
• W2316481657 creator A5040880164 @default.
• W2316481657 creator A5044510568 @default.
• W2316481657 creator A5050793689 @default.
• W2316481657 date "2016-04-07" @default.
• W2316481657 modified "2023-10-01" @default.
• W2316481657 title "<i>Anti</i>-3-¹⁸F-FACBC (¹⁸F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study" @default.
• W2316481657 cites W1520095978 @default.
• W2316481657 cites W1533336328 @default.
• W2316481657 cites W1830454849 @default.
• W2316481657 cites W1965447312 @default.
• W2316481657 cites W1965890948 @default.
• W2316481657 cites W1969862098 @default.
• W2316481657 cites W1976201938 @default.
• W2316481657 cites W1984079023 @default.
• W2316481657 cites W1984350421 @default.
• W2316481657 cites W1984460284 @default.
• W2316481657 cites W1996368241 @default.
• W2316481657 cites W2007026131 @default.
• W2316481657 cites W2009566449 @default.
• W2316481657 cites W2011046211 @default.
• W2316481657 cites W2031022390 @default.
• W2316481657 cites W2032988677 @default.
• W2316481657 cites W2033210286 @default.
• W2316481657 cites W2038087730 @default.
• W2316481657 cites W2039452519 @default.
• W2316481657 cites W2047620965 @default.
• W2316481657 cites W2066247404 @default.
• W2316481657 cites W2073672359 @default.
• W2316481657 cites W2098818525 @default.
• W2316481657 cites W2102944073 @default.
• W2316481657 cites W2135198751 @default.
• W2316481657 cites W2143531394 @default.
• W2316481657 cites W2147857878 @default.
• W2316481657 cites W2152505417 @default.
• W2316481657 cites W2239158335 @default.
• W2316481657 cites W2257069458 @default.
• W2316481657 doi "https://doi.org/10.2967/jnumed.115.171389" @default.
• W2316481657 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27056619" @default.
• W2316481657 hasPublicationYear "2016" @default.
• W2316481657 type Work @default.
• W2316481657 sameAs 2316481657 @default.
• W2316481657 citedByCount "49" @default.
• W2316481657 countsByYear W23164816572016 @default.
• W2316481657 countsByYear W23164816572017 @default.
• W2316481657 countsByYear W23164816572018 @default.
• W2316481657 countsByYear W23164816572019 @default.
• W2316481657 countsByYear W23164816572020 @default.
• W2316481657 countsByYear W23164816572021 @default.
• W2316481657 countsByYear W23164816572022 @default.
• W2316481657 countsByYear W23164816572023 @default.
• W2316481657 crossrefType "journal-article" @default.
• W2316481657 hasAuthorship W2316481657A5000322709 @default.
• W2316481657 hasAuthorship W2316481657A5014634237 @default.
• W2316481657 hasAuthorship W2316481657A5017822819 @default.
• W2316481657 hasAuthorship W2316481657A5019871221 @default.
• W2316481657 hasAuthorship W2316481657A5025282563 @default.
• W2316481657 hasAuthorship W2316481657A5028983768 @default.
• W2316481657 hasAuthorship W2316481657A5029771057 @default.
• W2316481657 hasAuthorship W2316481657A5036023937 @default.
• W2316481657 hasAuthorship W2316481657A5040880164 @default.
• W2316481657 hasAuthorship W2316481657A5044510568 @default.
• W2316481657 hasAuthorship W2316481657A5050793689 @default.
• W2316481657 hasBestOaLocation W23164816571 @default.
• W2316481657 hasConcept C121608353 @default.
• W2316481657 hasConcept C126322002 @default.
• W2316481657 hasConcept C142724271 @default.
• W2316481657 hasConcept C204232928 @default.
• W2316481657 hasConcept C2775842073 @default.
• W2316481657 hasConcept C2989005 @default.
• W2316481657 hasConcept C530470458 @default.
• W2316481657 hasConcept C71924100 @default.
• W2316481657 hasConceptScore W2316481657C121608353 @default.
• W2316481657 hasConceptScore W2316481657C126322002 @default.
• W2316481657 hasConceptScore W2316481657C142724271 @default.
• W2316481657 hasConceptScore W2316481657C204232928 @default.
• W2316481657 hasConceptScore W2316481657C2775842073 @default.
• W2316481657 hasConceptScore W2316481657C2989005 @default.
• W2316481657 hasConceptScore W2316481657C530470458 @default.
• W2316481657 hasConceptScore W2316481657C71924100 @default.
• W2316481657 hasIssue "9" @default.
• W2316481657 hasLocation W23164816571 @default.
• W2316481657 hasLocation W23164816572 @default.
• W2316481657 hasOpenAccess W2316481657 @default.
• W2316481657 hasPrimaryLocation W23164816571 @default.
• W2316481657 hasRelatedWork W2055479802 @default.
• W2316481657 hasRelatedWork W2209229671 @default.
• W2316481657 hasRelatedWork W2355548861 @default.
• W2316481657 hasRelatedWork W2364961773 @default.

• next